Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific Launches RNAi Services Laboratory, Supporting Researchers in Drug Discovery and Development

Published: Wednesday, June 20, 2007
Last Updated: Monday, July 02, 2007
Bookmark and Share
The laboratory offers advanced RNAi-based high-throughput screening and analysis, featuring Dharmacon technologies and expertise.

Thermo Fisher Scientific Inc. has opened a new RNAi Discovery and Therapeutic Services laboratory at its RNAi research and production center in Lafayette, Colorado, USA.

The new laboratory offers advanced RNAi (RNA-interference) screening and analysis services, as well as development of new therapeutic technologies involving RNAi.

"We have an industry-leading position in RNA- and RNAi-based technologies through our Dharmacon product line, now marketed under the Thermo Scientific brand," said Marc N. Casper, executive vice president of Thermo Fisher Scientific.

"Our core expertise in RNAi biology and therapeutic technology development, high-throughput screening, RNA chemistry and drug discovery research, combined with our unique portfolio of bioreagents, instrument systems and robotics, enables us to perform highly advanced contract services in-house. We can also offer customers the option of transferring this integrated workflow to their own facilities," Casper added.

The RNAi Discovery and Therapeutic Services laboratory features a highly integrated platform of Thermo Scientific technologies, including Dharmacon siRNA and miRNA libraries, BioImage and Cellomics high-content screening reagents and image analysis instrumentation, as well as robotics and software for laboratory automation.

"By providing RNAi-based screening on a contract basis, we will make it possible for any laboratory to realize the benefits of this important advancement in drug discovery," added Casper. "The RNAi Discovery and Therapeutic Services laboratory provides clients with access to unmatched scientific expertise and the ability to rapidly achieve meaningful results from this innovative workflow, while providing training and systems recommendations to clients establishing their own internal capabilities."

The RNAi contract services support researchers in pharmaceutical, biotechnology and academic fields by providing critical drug-discovery activities including target identification, target validation, biomarker discovery and RNAi therapeutic technology development.

The laboratory will also provide supplemental resources and expertise for overburdened labs already using RNAi technology. Services range from a single screen to multi- component projects, and include RNAi-based high-throughput screening and hit validation, high-content screening, microRNA expression profiling and analysis, as well as lab automation and integration. Therapeutic discovery and technology development is also available for clients pursuing RNAi-based therapeutics.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Scientific Signs Agreement with Novartis, Pfizer
Universal test designed for non-small cell lung cancer supports multiple drug development programs.
Thursday, November 26, 2015
Thermo's NGS Platform Selected for Nationwide Clinical Research Program
National Cancer Institute-MATCH trial to sequence thousands of tumor samples using Ion Torrent targeted sequencing technology.
Monday, June 01, 2015
Thermo Fisher Q3 Revenues up 31 Percent
Thermo Fisher announced that revenues grew 31% to $4.17 billion for the third quarter ended September 27, 2014.
Thursday, October 23, 2014
Thermo Reports 22% Revenue Rise in Q1 2014
Results include the addition of Life Technologies as of February 4, 2014, and exclude the previously announced related divestitures as of March 22, 2014.
Wednesday, April 23, 2014
Thermo Completes Life Tech Acquisition
The completion of the transaction follows the receipt of all required regulatory approvals.
Tuesday, February 04, 2014
Thermo Receives EC Clearance for Life Tech Acquisition
Thermo Fisher Scientific announced that it has received approval from the European Commission (EC) for its pending acquisition of Life Technologies Corporation.
Tuesday, November 26, 2013
Thermo Fisher Scientific Opens Its First Dry Powder Media Facility in APAC Region
Singapore facility delivers manufacturing redundancy and increases supply assurance for global biologic drug discovery and production.
Tuesday, August 06, 2013
Thermo Fisher Scientific Announces Application Deadlines for Life Sciences Scholarships
Thermo Scientific Pierce Scholarship Winter/Spring semester applications due December 14, 2012.
Wednesday, November 14, 2012
Thermo Fisher Scientific Expands Scientific Advisory Board
Dr. Klaus Lindpaintner to lead strategic development of innovative analytical technologies.
Thursday, November 08, 2012
Thermo Fisher Scientific Names Recipients of RNAi Discovery Grants
More than $400,000 in RNAi screening tools awarded to advance biomedical research and drug discovery.
Friday, November 06, 2009
Thermo Fisher Scientific Establishes RNAi Discovery Grant Program to Advance Gene Research
Five research projects to receive total of more than $400,000 in RNAi screening tools.
Friday, August 14, 2009
Thermo Fisher Scientific Collaborates with the Institute of Cancer Research to Create Proteomics Laboratory
The ICR's new, proteomics laboratory is equipped with a complete Thermo Scientific proteomics workflow.
Friday, July 24, 2009
Thermo Scientific Offering to be Highlighted at ISSCR Stem Cell Research Symposium
The symposium highlights the latest Thermo Scientific tools and technologies available to researchers to advance their understanding of stem cells.
Tuesday, July 07, 2009
Thermo Fisher Scientific Sponsors Shanghai Conference on Stem Cell Research
Thermo Scientific sponsors the 2009 Shanghai Symposium of Stem Cell Research and Regenerative Medicine at the Shanghai Tong Ji University.
Thursday, May 14, 2009
Thermo Fisher Scientific Welcomes New Members to RNAi Global Initiative
The new member institutions include the Children's Hospital of Eastern Ontario Research Institute and the University of Leiden in Amsterdam.
Monday, March 02, 2009
Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!